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HyaluronanAddition of ionic and nonionic polymers can improve the function of therapeutic surfactants in vitro and in
vivo, especially under conditions that tend to inhibit surfactant activity. Since surfactant proteins also act to
reduce surfactant inhibition, we studied the relative effects of a synthetic peptide (that mimics some of the
properties of a surfactant protein), polymers, and their combination on function of surfactant phospholipid
activity in vitro. We evaluated surface activity after adding polymers—polyethylene glycol or hyaluronan—to
a lipid mixture with or without the synthetic peptide, sinapultide (KL4). Using a pulsating bubble
surfactometer, we measured peptide/polymer effects separately or combined at two peptide concentrations.
Phospholipid mixtures, with or without KL4 or polymers, all demonstrated good surface activity. With serum
present as an inhibiting agent, adding either concentration of KL4 reduced inhibition. Mixtures containing
the higher concentration of KL4 required higher concentrations of serum for inhibition to occur. Adding
either polymer to mixtures with KL4 further decreased susceptibility to inhibition (required higher serum
concentrations). In the presence of serum, high molecular weight hyaluronan with KL4 at 0.4 mg/ml
improved surface activity to a greater degree than 0.8 mg/ml KL4 without polymer. If the beneﬁcial effects of
adding polymer to KL4–lipid mixtures are also borne out in the treatment of experimental lung injury, these
peptide–polymer surfactant combinations may eventually prove useful in the treatment of some forms of
acute lung injury in humans.Ave, San Francisco, CA 94110,
u).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
After secretion from alveolar type II cells, pulmonary surfactant
traverses a thin aqueous layer where it accumulates in the subsurface
space and adsorbs onto the air–liquid interface. Under normal
conditions, the interfacial surfactant then lowers surface tension,
thereby stabilizing airspaces [1–3]. The overall effect is to decrease the
work of breathing during inspiration, to prevent alveolar collapse, and
to maintain a reservoir of air in the lungs during expiration. Under
some abnormal conditions, for example after lung injury from a
variety of noxious agents (e.g., smoke, viral or bacterial pathogens),
lung inﬂammation ensues with leakage of serum from capillaries into
alveoli. Serum and other inﬂammatory constituents can inactivate
surfactant by a number of mechanisms [4]. In particular, serum
proteins adsorb to the air–liquid interface and inhibit surfactant
accumulation resulting in impaired surface activity and gas exchange
[5,6].
We and others have found that various ionic and non-ionic
polymers such as hyaluronan (HA), chitosan, polyethylene glycol
(PEG), dextran, as well as other substances like polymyxin canenhance surface activity of a number of surfactants in the presence of
inactivating substances such as serum, albumin, or meconium either
in vitro or in vivo [4,7–16].
SP-B, a hydrophobic surfactant protein, promotes the bilayer to
monolayer conversion of lipid vesicles, a process that leads to
adsorption of surfactant from the subsurface space to the air liquid
interface [17–19], and also prevents inhibition of surface activity of
surfactant lipid mixtures when inactivating substances are present
[20]. When SP-B is inhibited or absent in surfactant, lung function is
severely impaired [21,22].
KL4 was developed as a peptide analogue of SP-B. It is a positively
charged 21-residue helical peptide composed of repetitions of a motif
containing four hydrophobic leucines. In an investigational formula-
tion, lucinactant, (Surfaxin®, Discovery Laboratories, Inc., Warrington,
PA) KL4 is formulated by the addition of KL4 to dipalmitoyl
phosphatidylcholine (DPPC), palmitoyl-oleyl phosphatidylglycerol
(POPG) and palmitic acid. This formulation has been extensively
studied in vitro, in vivo and in clinical trials. Although details of the
KL4 interaction with lipid structures remain under investigation [23–
26], its ability to improve surface activity in vitro and its beneﬁcial use
in certain lung injuries are well established [27–31]. With these
ﬁndings in mind, we have tested whether the results we observed
when adding polymer to commercial exogenous surfactants derived
from animals [11,12] could be duplicated with lucinactant, a mixture
Table 1
Averages for mixtures of lucinactant±HA or PEG, absent serum are shown (n=5,
values represent means±SEM). An asterisk indicates p≤0.05 for comparisons of
polymer-supplemented samples with polymer-free samples using ANOVA corrected for
multiple comparisons by Tukey or Kruskal–Wallis tests.
0 Polymer HA 250 kDa,
0.25% (w/v)
HA 1240 kDa,
0.25% (w/v)
PEG 10 kDa,
5% (w/v)
Lucinactant 0.8 mg/ml +
Adsorption (mN/m) 20±0.5 21±0.8 24±1.5 22±0.7
STmin (mN/m) 10th cycle 3±1 1±0.3* 1±0.8* 0.4±0.3*
STmax (mN/m) 10th cycle 44±4 46±1 49±1 41±0.6
STmin (mN/m) 5 min 2±0.6 0.2±0.2* 0.2±0.2 0±0*
STmax (mN/m) 5 min 44±4 47±1 54±1 43±0.4
A10 (% area reduction) 24±4 24±2 25±1 24±1
Lucinactant 0.4mg/ml +
Adsorption (mN/m) 25±3 25±3 34±3 30±3
STmin (mN/m) 10th cycle 3.8±1 1.6±0.7 0±0* 3±1
STmax (mN/m) 10th cycle 45±1 46±1 66±2* 46±1
STmin (mN/m) 5 min 2±0.4 0.6±0.2* 0±0* 0.6±0.6*
STmax (mN/m) 5 min 48±1.5 48±0.2 67±2* 44±2
A10 (% area reduction) 30±4 31±1.5 16±3* 33±3
Lucinactant lipid +
Adsorption (mN/m) 32±2 35±1 33±1.5 36±3
STmin (mN/m) 10th cycle 0.6±0.4 0±0 3±1.6 8±4
STmax (mN/m) 10th cycle 50±1 54±0.2 63±5 49±2
STmin (mN/m) 5 min 0.2±0.2 0±0 1.4±1.4 6±3
STmax (mN/m) 5 min 52±0.7 54±0.2 64±4* 50±3
A10 (% area reduction) 27±1.6 34±3 25±4 41±3*
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vs. polymer, we carried out studies without KL4 and with two
concentrations of KL4 in the presence and absence of PEG or HA.
2. Methods
2.1. Materials
Lucinactant containing 0.8 mg/ml KL4, 22.5 mg/ml DPPC, 7.5 mg/
ml POPG and 4 mg/ml palmitic acid plus formulations containing zero
and 0.4 mg/ml KL4 were supplied by Discovery Laboratories, Inc.
Polyethylene glycol (PEG 10 kDa) and hyaluronan (HA 1240 kDa)
were obtained from Sigma Aldrich (St. Louis, MO). Hyaluronan (HA
250 kDa) was obtained from GlycoMed Research, Inc. (Hastings-on-
Hudson, NY). Serum with an approximate protein concentration of
70 mg/ml was obtained from adult, healthy, non-smoking volunteers
as sanctioned by our institutional research review board. Prior work in
our laboratory has found no differences in inhibitory capacity among
sera from healthy volunteers, those with ARDS [32], or with discarded
serum obtained from infants requiring exchange transfusion (unpub-
lished data).
2.2. Procedures
Before dilution, surfactant mixtures were: lipids (30 mg/ml);
lipids with 0.4 mg/ml KL4 and lipids with 0.8 mg/ml Kl4. These
mixtures were diluted to 1.25 mg total lipids/ml with buffer contain-
ing 2.5 mM HEPES with 0.9% NaCl and 2.5 mM CaCl2 adjusted to a pH
of 7.0. After dilution, the mixtures are referred to as lipids, KL4 0.4, or
KL4 0.8. Concentrations (w/v), and molecular weights of polymers
used were those we found effective in previous studies; that is, PEG
10 kDa, 5%; or HA 250 kDa or 1240 kDa, 0.25% [8] [7,12]. Dry polymers
were combined with the diluted lipid mixtures at room temperature
and dispersed by Vortex in 5-s bursts for 1–2 min until uniform in
appearance. Serum, when used, was added last and mixed as above.
Mixtures were tested alone, or with added PEG or HA in the presence
or absence of various concentrations of serum.
For these experiments, we used a modiﬁed pulsating bubble
surfactometer whose strengths and limitations in assessing surface
activity have been fully described [33]. The modiﬁcation is to avoid
leakage of surfactant ﬁlm into the capillary opening to minimize
differences in area that could affect the surface tension [34]. Samples
were placed in 25 µl chambers from which a 0.4 mm radius bubble
was drawn and surface tension of the static bubble was measured
over 40 s. The bubble was then inﬂated and deﬂated at a rate of 20
times per minute between a radius of 0.4 and 0.55 mmwhile pressure
was recorded. Surface tension was calculated by the Laplace formula:
P=ST/r, (where ST is surface tension, P is the inﬂating pressure, and r
is the bubble radius), assuming a spherical bubble shape. Sample
chambers were maintained at 37 °C during the measurements by
means of a temperature-controlled water jacket. The device was
calibrated by water manometer and by use of pure ﬂuids with known
surface tension.
Six indices of surface activity were recorded for the various
surfactant mixtures and each mixture was measured ﬁve times with
the results averaged:
1. The initial subphase to surface adsorption deﬁned as the value of
the surface tension 40 s after initial formation of a static bubble. A
low value indicates good adsorption.
2. Minimum surface tension measured after 30 s of inﬂation/
deﬂation cycling (10th cycle). STmin (10th cycle).
3. Maximum surface tension measured after 30 s of cycling (10th
cycle). STmax (10th cycle).
4. Minimum surface tension after 5 min of cycling. STmin (5 min).
5. Maximum surface tension after 5 min of cycling. STmax (5 min).6. An estimate of surface ﬁlm compressibility after 5 min of bubble
cycling obtained by calculating the percentage of surface area
reduction from its maximum value required for surface tension to
fall to 10 mN/m (A10). A low value indicates that the surface ﬁlm is
relatively non-compressible. If surface tension did not fall to
≤10 mN/m after maximal surface compression (that is when the
minimum bubble radius of 0.4 mm was reached), a limit of N47
was assigned, corresponding to the difference in area between
maximum and minimum bubble sizes.
Sufﬁcient serum was added to mixtures to increase the minimum
surface tension after 5 min of cycling to values above 10 mN/m,which
is used as the threshold for an effective surfactant [35]. Serum was
added in increments of 350 µg serum protein/ml to a maximum
concentration of 1400 µg/ml. The various mixtures were studied to
determine the serum concentration above which inhibition occurred.
2.3. Analysis
The data are presented as means±SEM. Measurements were
analyzed by one way analysis of variance (ANOVA) using SigmaStat
software (SPSS Science, Chicago, IL). Comparisons between pairs of
groups were done using the Tukey test or the Kruskal–Wallis test
when necessary to correct for multiple comparisons. P values≤0.05
were taken to indicate statistical signiﬁcance.
3. Results
3.1. No serum
The three surfactant mixtures without polymer (lipids alone, lipids
with KL4 0.4, and lipids with KL4 0.8) performed well with respect to
all measures of surface activity (Table 1). One notable and signiﬁcant
difference was an increase in initial surfactant adsorption when
comparing formulations with 0, 0.4 or 0.8 mg/ml KL4, resulting in
values of 32, 25, and 20 mN/m, respectively.
When polymer was added to the lipid mixtures with or without
KL4, only a few differences in surface activity were noted. All three
surfactant mixtures had higher maximum surface tensions after
Fig. 1.Data for lipidmixtures with or without added HA or PEG are shown after addition
of 350 µg/ml serum protein. Bars indicate minimum surface tension after 5 min of
cycling. In the presence of serum, HA, but not PEG, improves this measure of surface
activity (reduces serum inhibition). An asterisk indicates that a signiﬁcant difference
(pb0.05) exists between the lipid mixture without added polymer vs. the two lipid
mixtures with HA.
Fig. 2. Three measures of surface activity are compared for KL4 0.8 mg/ml surfactant
(solid bars); and KL4 0.4 mg/ml with 1240 kDa HA (open bars) in the presence of a high
serum concentration (1400 µg serum protein/ml). Note that addition of HA to the KL4
0.4 mg/ml mixture improves surface activity (reduces serum inhibition) signiﬁcantly
compared with KL4 0.8 mg/ml without polymer. Asterisks indicate that the differences
between contiguous bars are signiﬁcant (pb0.05).
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1240 kDa HA compared to mixtures with no polymer (16 vs. 30,
p=0.02), and A10 increased signiﬁcantly when PEG was added to
lipids without KL4 (41 vs. 27, p=0.03).
3.2. Lipid mixtures (absent KL4) with or without polymer with serum
Lipid mixtures, with or without PEG, were inhibited at the lowest
serum concentration (350 µg/ml). The addition of HA (MW of either
250 or 1240 kDa) increased the threshold of inhibition to above
350 µg/ml (Tables 4 and 5; Fig. 1). With HA, minimum surface tension
after 5 min of cycling was 8 or 9 mN/m compared to 29 mN/m
without HA (pb0.001). Other measures of surface activity also
improved considerably with the addition of HA to lipid mixtures.
For example, the minimum surface tension at the 10th cycle was 16
instead of 34 mN/m and the A10 was as low as 35 compared to N47
(for both comparisons, pb0.001).
3.3. KL4 0.4 with or without polymer (serum present)
Table 2 shows six measured surface activity indices for some
mixtures with KL4 0.4. For example, minimum surface tensions after
the 10th cycle and after 5 min for the 350 µg/ml serum mixture were
27 and 14 mN/m with no polymer. With HA 1240 kDa and 1400 µg/
ml serum, the values were 17 and 9 mN/m respectively. These
differences were signiﬁcant even though the serum concentration
was four times higher for the mixture with HA (pb0.001 for both
comparisons).
With this concentration of KL4 without polymer, lipid mixtures
were inhibited with 350 µg/ml of serum although surface activity
measures were improved (but not signiﬁcantly) compared to
mixtures without KL4. With the addition of HA 250 kDa, the threshold
for inhibition was between 350 and 700 µg/ml (Table 5). The effect ofTable 2
Lucinactant 0.4 mg/ml with two concentrations of serum±HA or PEG (n=5, values repres
Lucinactant 0.4 mg/ml +
0 Polymer+serum
350 µg/ml
HA 250 kDa+serum
350 µg/ml
HA 1240
350 µg/m
Adsorption (mN/m) 38±1 37±1.5 37±1
STmin (mN/m) 10th cycle 27±1 22±1.5 12±2*
STmax (mN/m) 10th cycle 42±1 40±1 54±2*
STmin (mN/m) 5 min 14±0.7 6±1* 7±1*
STmax (mN/m) 5 min 38±0.6 45±0.5* 51±3*
A10 (% area reduction) N47 40±0.7* 25±8*adding PEG further increased the threshold to between 700 and
1050 µg/ml. The addition of HA 1240 kDa raised the threshold to a
level greater than 1400 µg/ml serum (Fig. 2).
3.4. KL4 0.8 with or without polymer (serum present)
At this concentration of KL4 with a serum concentration of
1050 µg/ml, all mixtures with or without polymer performed well
(Table 3). When serum was increased to 1400 µg/ml, surface activity
with KL4 was inhibited. With addition of polymer, even at this high
concentration of serum, inhibition was largely prevented. With
1400 µg/ml serum, without polymer, the minimum surface tensions
after the 10th cycle and after 5 min were 34 and 25 mN/m.When PEG
was added, the surface tensions decreased signiﬁcantly to 22 and
3 mN/m respectively (pb0.001). With HA 1240 kDa, corresponding
values were 14 and 7 mN/m (pb0.001).
Threshold values for inhibition with serum, for all combinations of
lipids, KL4 and polymer, are summarized in Table 5. Lipids alone or
with PEG or the lower concentration of KL4 were readily inhibited
with low concentrations of serum, whereas mixtures with the higher
concentration of KL4 with polymer, were least inhibited even by high
concentrations of serum.
3.5. Maximum surface tensions
The maximal surface tensions tended to be highest with 1240 kDa
HA present in the mixtures, and highest in the absence of KL4 and
serum (Tables 1–4).
4. Discussion
The primary results of this study show that both KL4 peptide and
polymers improve surface activity of surfactant lipids in the presenceent means±SEM). An asterisk indicates signiﬁcance as described in Table 1.
kDa+serum
l
PEG+serum
350 µg/ml
HA 1240 kDa+serum
1400 µg/ml
PEG 10 kDa+serum
1400 µg/ml
38±1 38±0.4 42±2
18±1* 17±2* 31±1
46±1 54±2* 49±1
5±0.4* 9±0.6* 22±1
49±1* 49±2* 45±1
39±1* 29±5* N47
Table 3
Lucinactant 0.8 mg/ml with serum 1400 µg/ml±HA or PEG (n=5, values represent means±SEM). An asterisk indicates signiﬁcance as described in Table 1.
Lucinactant 0.8 mg/ml +
0 Polymer+serum 1400 µg/ml HA 250 kDa+serum 1400 µg/ml HA 1240 kDa+serum 1400 µg/ml PEG 10 kDa+serum 1400 µg/ml
Adsorption (mN/m) 43±2 35±1* 31±0.4* 40±1
STmin (mN/m) 10th cycle 34±1 20±2* 14±0.6* 22±1*
STmax (mN/m) 10th cycle 47±1 37±2* 43±1 43±1
STmin (mN/m) 5 min 25±2 4±2* 7±2* 3±0.5*
STmax (mN/m) 5 min 43±1 46±1 46±2 46±0.2
A10 (% area reduction) N47 40±1* 35±5* 34±1*
Table 5
Different lipid, KL4, and polymer mixtures are listed next to the concentrations of serum
protein necessary for inhibition as deﬁned in the text. In general the mixtures with the
higher concentration of KL4 that include polymer, particularly HA 1240 kDa, are the
most resistant to inhibition.
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to inhibition with serum to a greater degree than either alone, at least
within the range of the concentrations studied (Table 5). The addition
of HA to lipids raises the inhibition threshold to more than 350 µg/ml
of serum, a result superior to adding 0.4 KL4 without polymer.
Addition of polymers with the lower concentration of KL4 improves
surface activity to a greater degree than doubling the concentration of
KL4. These results suggest (but do not prove) that the effects of KL4
and polymers may differ and are additive.
Maximal surface tensions tended to be highest in mixtures with
high molecular weight HA although these mixtures had the lowest
minimal surface tensions and low surface ﬁlm compressibility on
reduction of ﬁlm surface area (decreased bubble size). Higher
concentrations of KL4 with HA tended to lower maximal surface
tensions. The physiological signiﬁcance of changes in maximal surface
tension is less well understood than changes in minimal surface
tension. Maximal surface tension is affected by many factors such as
ﬁlm collapse pressure and re-spreading rates, dilatational viscosity of
the surface ﬁlm, diffusivity of surfactant particles in the bulk phase
(and hence viscosity of the bulk phase), and other conditions. In prior
work we have measured the viscosity effects of HA with surfactant
mixtures under a variety of conditions [36].
KL4 is a simple peptide that in some respects has been found to
mimic the effects of SP-B when added to surfactant lipids [37].
Presumably KL4 is not affected by the puriﬁcation and reconstitution
methods that may alter the function of native surfactant proteins
when added to surfactant lipids. Whether additive effects between
peptide and polymer as we have found in this study also occur with
native SP-B is under current investigation.
SP-A and SP-B have long been known to enhance surfactant
surface adsorption and to maintain surface activity in the presence of
some inhibitors [20,38,39]. Hall and others have shown that SP-B
catalyzes the transformation of the surfactant bilayer in the subphase
to amonolayer at the air–surface interface, allowing surfactant to alter
surface tension [18,40]. Whether both effects (enhanced adsorption
and decreased inhibition) occur by a similar mechanism is not known.
HA and PEG have a variety of attributes that may be critical for
reducing surfactant inhibition by serum. Both have a high afﬁnity for
binding water. HA has the highest water binding capacity and also has
the ability to self-aggregate. These propertiesmay segregate inhibitors
from surfactant components. While HA binds to various proteins, to
date there is no report of speciﬁc HA–surfactant protein interactions.Table 4
Lucinactant lipids with 350 µg/ml serum±HA or PEG 10 (n=5, values represent
means±SEM). An asterisk indicates signiﬁcance as described in Table 1.
Lucinactant lipid +
0 Polymer HA 250 kDa HA 1240 kDa PEG 10 kDa
Adsorption (mN/m) 44±1 38±1 35±0.5* 45±2
STmin (mN/m) 10th cycle 34±1.6 16±1* 16±2* 34±2
STmax (mN/m) 10th cycle 51±1.5 43±2* 48±2 52±2
STmin (mN/m) 5 min 29±1.5 8±2.5* 9±1* 23±2
STmax (mN/m) 5 min 48±1 42±5 48±3 48±1
A10 (% area reduction) N47 42±2* 35±5* N47On the other hand HA has been found to bind to simple lipids [41]
and affect lipid structure [42] [43]. When HAs of 170, 740, and
1900 kDa are mixed with DPPC or egg lecithin, electron microscopy
reveals aggregates and sheets of lipids in contrast to the vesicular
forms seen in the absence of HA [44]. The formation of these
aggregates may affect surfactant adsorption.
PEG also has the ability to aggregate lipids [45,46]. The enhanced
adsorption of surfactant–polymer mixtures in the presence serum
inhibition can also be explained using a depletion attraction model
[47–50]. Large surfactant aggregates are pushed towards each other
and the interface by an osmotic pressure induced by the exclusion
(“depletion”) of the polymer from the space between the surfactant
aggregates and the interface. This depletion attraction is sufﬁciently
strong that it can overcome (to a degree) the electrostatic and steric
repulsion imposed by serum proteins adsorbed on the interface. The
increased surfactant adsorption helps to drive the serum from the
interface, resulting in a reversal of the inactivation. The charge
carried by HA may explain why HA can reduce inhibition at lower
weight fractions than the neutral, lower molecular weight polymer,
PEG [48].
The relevance of in vitro results to possible effects that may occur
in the vastly more complex lung is always problematic. Because of the
limitations of our assay, we used much lower concentrations of
surfactant and total serum protein than found in injured lungs. The
best estimates of alveolar ﬂuid protein concentrations are from
Ishizaka et al. [51]. They ﬁnd about 25 mg albumin/ml of undiluted
alveolar ﬂuid in ARDS patients vs. 5 mg/ml for volunteers with
healthy lungs. Since estimates of surfactant concentrations in the lung
of ARDS patients are slightly reduced from normal, we assume a
surfactant concentration in situ of 20–70 mg/ml, whichwould imply a
protein to surfactant ratio of approximately 1:1 to 1:3 (w/w) in
patients with ARDS. For our measurements of surface activity, we are
using a maximal serum protein concentration of 1.4 mg protein to
1.25 mg surfactant, which is roughly the ratio that we estimate above
for patients with ARDS. In general, results reported here are consistent
with our previous ﬁndings when polymers are added to variousSerum protein (μg/ml) Mixture
N1400 KL4 0.8+PEG
KL4 0.8+HA 250 kDa
KL4 0.8+HA 1240 kDa
KL4 0.4+HA 1240 kDa
N700 and b1050 KL4 0.8
KL4 0.4+PEG
N350 and b700 KL4 0.4+HA 250 kDa
Lipids+HA 250 kDa
Lipids+HA 1240 kDa
b350 KL4 0.4
Lipids
Lipids+PEG
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tested in animal models of lung injury [7,8].
5. Conclusions
Addition of polymer can substantially improve the surface activity
of KL4 surfactant mixtures in the presence of serum. Of special note is
the ﬁnding that adding HA 1240 kDa to KL4 0.4 demonstrated better
surface activity than KL4 0.8 without polymer. This result also
indicates that the useful threshold for KL4 addition to lipid mixtures
can be lowered from 0.8 to 0.4 mg/ml in the presence of HA 1240 kDa.
Alternatively, one could use the higher peptide level with HA
1240 kDa and achieve even greater resistance to inhibition of surface
activity. PEG was also found to substantially improve surface activity
when added to KL4 mixtures presumably due to depletion forces.
These results suggest that future in vivo studies using KL4 and
polymer are warranted and may lead to new surfactant formulations
that may be effective in diseases with signiﬁcant protein leak into
alveolar spaces. These new synthetic peptide–polymer surfactants
would have the advantages of increased reproducibility, improved
safety, and possibly reduced cost.
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